🎁 💸 Warren Buffett's Top Picks Are Up +49.1%. Copy Them to Your Watchlist – For FreeCopy Portfolio

France's Doctolib raises 35 million euros to speed expansion in Germany

Published 28/11/2017, 05:12
© Reuters. Stanislas Niox-Chateau, Co-Founder & CEO of  Doctolib, poses at the entrance of the company's headquarters in Paris
VIV
-
EURA
-

By Mathieu Rosemain

PARIS (Reuters) - French start-up Doctolib, an online booking platform for doctors, brought in listed investment firm Eurazeo (PA:EURA) in a 35 million euro (31.5 million pounds) fundraising aimed at speeding up its expansion in Germany, it said on Tuesday.

Eurazeo, which manages about 6 billion euros including stakes in Europe's biggest hotels group AccorHotels and luxury clothing maker Moncler, injected half of the sum, strengthening Doctolib's investment profile.

France's state-owned investment bank invested the other half, bringing the total raised so far this year by Doctolib to 61 million euros -- one of the top five investments made in a French start-up so far this year.

"We hadn't planned to do this at all," chief executive and co-founder Stanislas Niox-Chateau said, referring to the latest fundraising.

"But since France is soaring and results in Germany are better than expected, we advanced our fundraising by about six to nine months," he said.

The Paris-based company is four years old and has grown thanks to higher demand for seamless bookings, whether for hotel rooms, cars or doctors.

The company employs 380 people and plans to hire an additional 200 next year, half of them in Germany. All its revenue comes from the 30,000 French physicians who have subscribed to its online service for 109 euros a month.

Doctolib's software aims to cut the so-called "no show" rate, or the number of people who do not turn up for their medical appointments.

It also seeks to ease doctors' day-to-day communication with patients and other healthcare professionals.

Doctolib's strategy of serving physicians first has enabled it to take a leading position in France, Niox-Chateau said, despite competition from many other platforms.

These include MonDocteur, a platform backed by a subsidiary of media group Lagardere, and RDVmédicaux, backed by its French rival Vivendi (PA:VIV).

Doctolib's shareholders also include U.S. venture capital firm Accel and individual investors such as Nicolas Brusson, co-founder of car-sharing app BlaBlaCar, Pierre Kosciusko-Morizet, co-founder of online market place PriceMinister and Ludwig Klitzch, chief executive of Germany's family-owned healthcare group Ideamed.

Doctolib's total subscriptions generate about 40 million euros. It aims to reach breakeven by 2020, although this is not a firm target, Niox-Chateau said.

© Reuters. Stanislas Niox-Chateau, Co-Founder & CEO of  Doctolib, poses at the entrance of the company's headquarters in Paris

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.